Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Roivant Sciences Ltd. (ROIV) has a Wall Street consensus price target of $31.25, based on estimates from 14 covering analysts. With the stock currently trading at $28.94, this represents a potential upside of +8.0%. The company has a market capitalization of $1.12B.
Analyst price targets range from a low of $30.00 to a high of $33.00, representing a 10% spread in expectations. The median target of $31.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 13 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ROIV trades at a trailing P/E of -120.6x.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ROIV stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for ROIV is $31.25, close to the current price of $28.94 (8.0% implied move). Based on 14 analyst estimates, the stock appears fairly valued near current levels.
ROIV has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 13 Buy/Strong Buy ratings. The consensus 12-month price target of $31.25 implies 8.0% upside from current levels.
ROIV's current price is $28.94 with a consensus target of $31.25 (8.0% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $33 for ROIV, while the most conservative target is $30. The consensus of $31.25 represents the median expectation. These targets typically reflect 12-month expectations.
ROIV is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 13 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ROIV stock forecast based on 14 Wall Street analysts shows a consensus price target of $31.25, with estimates ranging from $30 (bear case) to $33 (bull case). The median consensus rating is "Buy".
ROIV appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $31.25 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ROIV analyst price targets range from $30 to $33, a 10% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $31.25 consensus represents the middle ground.